Antitumor effects and immune‐mediated adverse events of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma

Documenti analoghi

• A novel approach to evaluate the therapeutic efficacy of durvalumab and tremelimumab combination therapy in hepatocellular carcinoma
  di: Tetsu Tomonari, et al.
  Pubblicazione: (2025)
• Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma
  di: Takanori Ito, et al.
  Pubblicazione: (2025)
• Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child–Pugh Class B
  di: Ryu Sasaki, et al.
  Pubblicazione: (2025)
• Initial treatment efficacy and safety of durvalumab plus tremelimumab combination therapy in unresectable hepatocellular carcinoma in clinical practice
  di: Tetsu Tomonari, et al.
  Pubblicazione: (2024)
• Significance of changes in tumor markers in patients treated with durvalumab plus tremelimumab combination therapy as a surrogate marker for tumor response to unresectable hepatocellular carcinoma
  di: Shinsuke Uchikawa, et al.
  Pubblicazione: (2024)